We’re improving our website: We’re making improvements to the look and navigation of our website to make it easier to find the information you need. You may notice some pages looking a little different while these updates are being made.
Nivolumab-relatlimab for untreated unresectable or metastatic melanoma in people aged 12 to 17 years, Policy Position Statement (PPS343), October 2026 (PDF, 495Kb)
Nusinersen for treating children and young people up to 17 years old with spinal muscular atrophy, Policy Position Statement (PPS191), August 2025.pdf (PDF, 485Kb)
Selective Dorsal Rhizotomy (SDR) for the treatment of spasticity in cerebral palsy in children aged 3-9 years, Policy Position Statement (PP245), March 2024.pdf (PDF, 975Kb)
Selpercatinib for advanced thryoid cancer with RET alterations untreated with a targeted cancer drug in people aged 12-17 years, Policy Position Statement (PPS340), September 2026 (PDF, 418Kb)
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over, Policy Position Statement 9PPS321), April 2026 (PDF, 403Kb)
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6-17 years of age, Policy Position Statement (PPS298), April 2025.pdf (PDF, 406Kb)